SurvivorNet on MSN
CELMoDs: The next-generation drugs that could replace Revlimid in myeloma treatment
Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand ...
The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained. The landscape of relapsed or refractory multiple ...
Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We have a lot of new types of therapies in ...
There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after reporting positive results in a phase 3 trial. Full data from the ...
Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy ...
Finding uncovers a key property needed for CELMoD drugs, a type of protein degrader, to work effectively. Scientists at Scripps Research have uncovered a critical feature that a promising new class of ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Scientists at Scripps Research have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. CELMoDs are designed to attack cancer in a novel ...
Although survival rates for patients with multiple myeloma are improving, with a 5-year rate of about 60%, many patients relapse after treatment. "Patients have seen impressive advances in survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results